(Q34294904)

1 August 2017

1 reference

title

Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections? (English)

1 reference

invasive fungal infections

1 August 2017

1 reference

1 reference

Ellis M

1

1 reference

1 August 2017

publication date

1 June 2000

1 reference

Transplant Infectious Disease

1 August 2017

published in

1 reference

1 August 2017

volume

2

1 reference

1 August 2017

issue

2

1 reference

1 August 2017

page(s)

51-61

1 reference

Favorable outcome of invasive aspergillosis in patients with acute leukemia

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Influence of six antifungal agents on the chemiluminescence response of mouse spleen cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Pretreatment regimens for adverse events related to infusion of amphotericin B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Double-blind randomized study of the effect of infusion rates on toxicity of amphotericin B

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Do variations in molecular structure affect the clinical efficacy and safety of lipid-based amphotericin B preparations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Safety of amphotericin B colloidal dispersion

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Allergic reactions and other rare side-effects of liposomal amphotericin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Dose-dependent antifungal activity and nephrotoxicity of amphotericin B colloidal dispersion in experimental pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Efficacy of escalating doses of liposomal amphotericin B (AmBisome) against hematogenous Candida lusitaniae and Candida krusei infection in neutropenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Phase I study of amphotericin B colloidal dispersion for the treatment of invasive fungal infections after marrow transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Lipid formulations of amphotericin B: clinical efficacy and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Amphotericin B liposomes with prolonged circulation in blood: in vitro antifungal activity, toxicity, and efficacy in systemic candidiasis in leukopenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

In-vitro effects of liposome-encapsulated amphotericin B (AmBisome) and amphotericin B-deoxycholate (Fungizone) on the phagocytic and candidacidal function of human polymorphonuclear leucocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Treatment of acute myeloid leukemia with cytokines: effect on duration of neutropenia and response to infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

Lipid formulations for amphotericin B: does the emperor need new clothes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Distribution and activity of amphotericin B in humans

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Treatment of disseminated mycotic infectioons. A new approach to amphotericin B therapy

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Effect of immunosuppression and amphotericin B on Aspergillus antigenemia in an experimental model

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Combination Therapy of Experimental Candidiasis, Cryptococcosis and Aspergillosis in Mice

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Accumulation of amphotericin B in human macrophages enhances activity against Aspergillus fumigatus conidia: quantification of conidial kill at the single-cell level

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxicity in bone marrow transplant patients and leukemia patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Amphotericin B lipid complex (ABLC) for the treatment of confirmed or presumed fungal infections in immunocompromised patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Severe and common side-effects of amphotericin B lipid complex (Abelcet)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Liposomal Amphotericin B (AmBisome) Therapy in Invasive Fungal Infections

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Liposomal amphotericin B (AmBisome) treatment of invasive fungal infections in immunocompromised children

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Th1 and Th2 cytokines in mice with invasive aspergillosis.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1399-3062.2000.020203.X

7 January 2021

10.1034/J.1399-3062.2000.020203.X

Identifiers

DOI

1 reference

1 August 2017

1 reference